• SLC3A2在慢性阻塞性肺病中的表达及其与炎症的关系
  • 武小杰.SLC3A2在慢性阻塞性肺病中的表达及其与炎症的关系[J].内科急危重症杂志,2024,30(5):401-403
    扫码阅读全文 本文二维码信息
    DOI:10.11768/nkjwzzzz.20240504
    中文关键词:  慢性阻塞性肺病  溶质转运载体家族3成员2  氨基酸代谢  炎症机制
    英文关键词:
    基金项目:武汉市卫健委科研项目(WX21Q07)
    作者单位E-mail
    武小杰 武汉市第一医院 244135490@qq.com 
    摘要点击次数: 230
    全文下载次数: 253
    中文摘要:
          摘要 目的:探讨溶质转运载体家族3成员2(SLC3A2)在慢性阻塞性肺病(COPD)发生机制中的作用。方法:收集72例COPD稳定期患者纳入COPD组,另选取67例同期健康体检者为对照组。采集2组外周静脉血,通过密度梯度离心和红细胞裂解的方法分离出中性粒细胞,采用蛋白免疫印迹法检测外周血中性粒细胞SLC3A2水平,酶联免疫吸附(ELISA)法检测血浆中白介素(IL)-8水平,同时收集2组的肺功能指标,包括第1秒用力呼气容积(FEV1)、用力肺活量(FVC)。分析SLC3A2与IL-8、FEV1/FVC、FEV1%预计值的相关性。结果:COPD组外周血中性粒细胞的SLC3A2及IL-8水平高于对照组(P均<0.01),SLC3A2与IL-8呈正相关(r=0.45,P<0.01),与FEV1/FVC、FEV1%预计值呈负相关(r=-0.42,-0.45,P均<0.01)。结论:SLC3A2可能通过炎症反应参与COPD的发生,SLC3A2有可能成为COPD临床的炎症标志物和治疗的靶点。
    英文摘要:
          Abstract Objective: To investigate the role of solute carrier family 3 member 2 (SLC3A2) in the pathogenesis of chronic obstructive pulmonary disease (COPD).Methods: A total of 72 patients with stable COPD were included in the COPD group,and 67 healthy subjects served as the control group. Peripheral venous blood was collected from both groups,and neutrophils were isolated by density gradient centrifugation and red cell lysis. SLC3A2 levels in peripheral blood were detected by Western blotting and interleukin-8 (IL-8) in plasma was detected by enzyme-linked immunosorbent assay (ELISA). At the same time, the pulmonary function indexes, including forced expiratory volume in the first second(FEV1) and forced vital capacity (FVC) were determined. The correlation between SLC3A2 and IL-8, FEV1/FVC, FEV1% predicted values was analyzed. Results: The levels of SLC3A2 and IL-8 in peripheral blood neutrophils in COPD group were higher than those in control group (all P< 0.01). SLC3A2 was positively correlated with IL-8 (r=0.45, P< 0.01), and negatively correlated with FEV1/FVC and FEV1% predicted values (r=-0.42, -0.45, all P< 0.01). Conclusion: SLC3A2 may participate in the occurrence of COPD by inflammatory response, and SLC3A2 may become a clinical inflammatory marker and a therapeutic target.